RxDoctor Payments Data

Gerald Norris, MD

Internal Medicine · Birmingham, ALNPI 1619941838

Payments from drug & device makers

$2,899in general payments, 2019–2025

Across 190 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$630
  • AbbVie$466
  • Lilly USA, LLC$438
  • Pfizer$409
  • Boehringer Ingelheim$147
  • Bayer$141
  • plus $668 from 18 others

What the payments were for

  • Food & beverage$2,899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,899 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$250,467
Medicare patients
364
Services billed
11,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide321$322,553
JardianceEmpagliflozin226$186,015
EliquisApixaban202$167,979
MounjaroTirzepatide108$122,338
FarxigaDapagliflozin Propanediol111$86,760
TrulicityDulaglutide77$80,251
MyrbetriqMirabegron86$57,027
Repatha SureclickEvolocumab43$29,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$29,136
XareltoRivaroxaban36$26,166
InvokanaCanagliflozin27$20,318
GemtesaVibegron28$17,612
Fiasp FlextouchInsulin Aspart (Niacinamide)11$14,285
RybelsusSemaglutide13$14,203
Atorvastatin Calcium1,082$12,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$630$336,756334 claims
Lilly USA, LLCMounjaro, Trulicity$438$202,589185 claims
Boehringer IngelheimJardiance$147$186,015226 claims
PfizerEliquis$409$167,979202 claims
AstraZenecaFarxiga, Brilinta$70$92,045123 claims
Astellas Pharma US IncMyrbetriq$67$57,02786 claims
GSKTrelegy Ellipta$103$29,13641 claims
Sumitomo Pharma America, Inc.Gemtesa$14$17,61228 claims
BayerKerendia$141$12,97114 claims
AbbVieLinzess$466$11,55114 claims
NovartisEntresto$37$6,38813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →